Valneva SE announced the earnings guidance for 2024. For the year Product sales expected between ?150 million and ?180 million, reflecting continued revenue growth for proprietary products and IXCHIQ®?s launch-year sales, despite anticipated supply constraints for third-party products and IXIARO®.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.444 EUR | -0.06% | -5.95% | -27.03% |
Apr. 11 | Valneva: Deep Track Biotechnology Master holds less than 5% of the capital | CF |
Mar. 26 | Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.03% | 510M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- VLA Stock
- News Valneva
- Valneva Se Announces Earnings Guidance for 2024